← Patent-cliff monitor small molecule XOFLUZA BALOXAVIR MARBOXIL
Loss of exclusivity October 2039 latest FDA-listed patent expiry
Company Genentech → See this company's full patent-cliff portfolio Drug detail Brand name XOFLUZA Active ingredient BALOXAVIR MARBOXIL Strength 40MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval October 2018 Marketing status RX
Listed patents Patent Expires Type 12064438 October 2039 product 11261198 September 2038 product 11306106 August 2037 use U-3000 10759814 August 2037 substance, product 10392406 April 2036 substance 10633397 April 2036 use U-3000 8987441 October 2032 substance, product 8927710 May 2031 product 9815835 June 2030 product
Regulatory exclusivity Code Expires M-187 December 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.